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Abstract 30 
Peroxisomes are ubiquitous cell organelles essential for human health. To maintain a healthy 31 
cellular environment, dysfunctional and superfluous peroxisomes need to be selectively 32 
removed. Although emerging evidence suggests that peroxisomes are mainly degraded by 33 
pexophagy, little is known about the triggers and molecular mechanisms underlying this 34 
process in mammalian cells. In this study, we show that PEX5 proteins fused to a bulky C-35 
terminal tag trigger peroxisome degradation in SV40 large T antigen-transformed mouse 36 
embryonic fibroblasts. In addition, we provide evidence that this process is autophagy-37 
dependent and requires monoubiquitination of the N-terminal cysteine residue that marks 38 
PEX5 for recycling. As our findings also demonstrate that the addition of a bulky tag to the C 39 
terminus of PEX5 does not interfere with PEX5 monoubiquitination but strongly inhibits its 40 
export from the peroxisomal membrane, we hypothesize that such a tag mimics a cargo 41 
protein that cannot be released from PEX5, thus keeping monoubiquitinated PEX5 at the 42 
membrane for a sufficiently long time to be recognized by the autophagic machinery. This in 43 
turn suggests that monoubiquitination of the N-terminal cysteine of peroxisome-associated 44 
PEX5 not only functions to recycle the peroxin back to the cytosol, but also serves as a 45 
quality control mechanism to eliminate peroxisomes with a defective protein import 46 
machinery. 47 
48 
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Introduction 49 
To maintain a healthy intracellular environment, cells need to eliminate excessive and 50 
dysfunctional organelles. This turnover mainly occurs within the lysosome in a process called 51 
autophagy. Currently, 3 major autophagy pathways have been characterized in eukaryotic 52 
cells: macroautophagy, microautophagy, and chaperone-mediated autophagy.1-3 During 53 
macroautophagy—hereafter simply referred to as autophagy—a cup-shaped double 54 
membrane-bound structure, called the phagophore, is formed in the cytoplasm. This structure 55 
elongates to engulf the cargo and eventually becomes a cargo-laden short-lived organelle 56 
known as the autophagosome. The intra-autophagosomal components are, upon 57 
autophagosome-lysosome fusion, finally degraded by lysosomal hydrolases. 58 
Autophagy is mainly mediated by AuTophaGy-related (ATG) proteins, of which at 59 
least 38 have been identified in yeast.4,5 Of these, less than half are thought to be required for 60 
canonical autophagy, which is a highly conserved process among eukaryotes.4 Autophagy 61 
occurs both selectively and nonselectively, and—in contrast to bulk autophagy—selective 62 
autophagy pathways require the additional specific action of autophagy receptors (e.g., 63 
SQSTM1/p62, NBR1, and OPTN).6,7 These receptors act independently, or concertedly, to 64 
bridge substrates targeted for degradation with the elongating phagophore via tethering of 65 
both structures. Substrate binding generally occurs through a ubiquitin-binding domain, and 66 
the binding to the phagophore via an LC3-interacting region.7 Microtubule-associated protein 67 
1 light chain 3 alpha (MAP1LC3A) and its homologs are present on the phagophore convex 68 
and concave membranes, where they—among other functions—mediate the specificity of 69 
selective autophagy.7 70 
Peroxisomes are dynamic organelles that rapidly adapt their size, protein content, and 71 
number in response to altering environmental conditions. Important functions of peroxisomes 72 
in mammals include α- and β-oxidation of fatty acids and the biosynthesis of plasmalogens 73 
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and docosahexaenoic acid.8-10 Importantly, as (i) peroxisomal enzymes produce vast amounts 74 
of reactive oxygen species (ROS) as part of their catalytic cycle,11 and (ii) ROS are involved 75 
in an array of signaling pathways,12 these organelles are also increasingly being recognized as 76 
important redox signaling platforms.13,14 77 
To perform their various functions, peroxisomes require an operational and efficient 78 
import machinery for matrix proteins. The vast majority of these proteins contain a 79 
peroxisomal targeting signal type 1 (PTS1), made up of a C-terminally located tripeptide with 80 
the consensus sequence (S/A/C)-(K/R/H)-(L/A) (in single-letter amino acid code).15,16 PTS1-81 
containing proteins are recognized in the cytosol by the peroxisomal matrix protein import 82 
receptor PEX5, which interacts with the PTS1 via 6 tetratricopeptide repeats (TPRs) that are 83 
located in its C terminus.17 Importantly, the mammalian PEX5 transcript undergoes 84 
alternative splicing yielding 2 major isoforms, PEX5(S) (the short variant) and PEX5(L) (the 85 
long variant), the latter of which is also involved in PTS2-import.18 Upon cargo recognition, 86 
the protein complex is transported to the peroxisomal membrane where PEX5 docks on the 87 
docking/translocation machinery (DTM), consisting of the peroxins PEX13, PEX14, and the 3 88 
RING proteins PEX2, PEX10, and PEX12.19,20 The PEX5-cargo protein complex is then 89 
inserted into the DTM with the concomitant translocation of the cargo protein into the 90 
organelle matrix. Finally, DTM-inserted PEX5 is monoubiquitinated on an evolutionarily 91 
conserved cysteine residue (in humans and mice at amino acid position 11) and subsequently 92 
extracted from the peroxisomal membrane in an ATP-dependent manner by the receptor 93 
export machinery.21,22 This machinery, often called ‘REM’23 or ‘exportomer’,24 consists in 94 
mammals of the core proteins PEX1 and PEX6, 2 AAA+ ATPases that can interact and form a 95 
heterohexameric ring complex.25,26 96 
Over the last decades, it has become increasingly clear that mammalian peroxisomes 97 
are degraded via selective autophagy (a process known as ‘pexophagy’).27-32 This is perhaps 98 
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best illustrated by the observation that proliferated rat peroxisomes are rapidly turned over in 99 
an autophagy-dependent manner upon removal of the proliferation stimulus.27,28 100 
Unfortunately, little is currently known about the physiological triggers and molecular 101 
mechanisms underlying mammalian pexophagy. However, since (i) peroxisomes—like 102 
mitochondria—produce large amounts of ROS as part of their metabolism,11 (ii) excessive 103 
organelle-specific ROS-generation causes mitochondria- and endoplasmic reticulum-selective 104 
degradation in mammalian cells,33-35 and (iii) highly oxidized peroxisomes can be degraded 105 
via pexophagy in Hansenula polymorpha and Arabidopsis thaliana,36,37 it is tempting to 106 
speculate that mammalian pexophagy can be triggered via ROS-related mechanisms. 107 
Finally, accumulating evidence points towards an integral role of ubiquitin in the 108 
targeting of mammalian peroxisomes to autophagosomes.30,32,38 For example, ectopic 109 
expression of peroxisomal membrane proteins (PMPs) attached to cytosolically exposed 110 
ubiquitin triggers pexophagy in a SQSTM1-dependent manner.38 In addition, overexpression 111 
of both NBR1 and PEX3 has been demonstrated to induce pexophagy in a ubiquitin-112 
dependent fashion.30,32 However, endogenous PMPs that are ubiquitinated during pexophagy 113 
have not yet been identified. Nevertheless, a proposed candidate is PEX5,30,39 which—as 114 
mentioned above—is known to be monoubiquitinated on a cysteine residue (Cys11 in human 115 
and mouse PEX5) at the peroxisomal membrane during its normal import cycle.21 In addition, 116 
it has recently been shown that cytosolic PEX5 can also be ubiquitinated at Lys527, probably 117 
the result of a yet uncharacterized quality control process.40 In this study, we provide evidence 118 
that expression of Cys11-monoubiquitinatable but export-deficient variants of PEX5 trigger 119 
peroxisome degradation in SV40 large T antigen-transformed (SV40T) mouse embryonic 120 
fibroblasts (MEFs). This finding strongly indicates that the amount of Cys11-121 
monoubiquitinated PEX5 at the peroxisomal membrane may function as a quality control 122 
mechanism to eliminate peroxisomes with a defective/jammed protein import machinery. 123 
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Results 124 
Expression of PEX5 proteins fused to a bulky C-terminal tag triggers peroxisome 125 
removal in SV40T-MEFs 126 
To gain more insight into potential triggers for peroxisome degradation in mammalian 127 
cells, we first tested the hypothesis that these organelles can be selectively removed upon 128 
oxidative damage. To generate oxidative stress in the peroxisomal matrix or at the 129 
peroxisomal membrane in a temporally controlled manner, we designed a set of KillerRed 130 
(KR)-fusion proteins. KR is a genetically-encoded photosensitizer that generates ROS upon 131 
green light illumination.41 Intriguingly, although we were unable to show an increase in 132 
peroxisome turnover upon photoactivation of peroxisomal matrix-targeted KR,42 we found 133 
that overexpression of nonphotoactivated human (Homo sapiens, Hs) PEX5(L)-KR in 134 
SV40T-MEFs already resulted in a partial or complete disappearance of peroxisomes in a 135 
large number of cells, as detected by immunofluorescence with anti-PEX14 antibodies (Fig. 136 
1A). As such a phenotype was not discernible in cells overexpressing only PEX5(L) or KR 137 
(Fig. 1B and C, respectively), we next investigated whether or not overexpression of other 138 
PEX5-fusion proteins could also induce peroxisome removal. Note that, to facilitate the 139 
identification of transfected cells, the indicated test plasmids were routinely cotransfected 140 
with a plasmid encoding mitochondria-targeted EGFP. In addition, to quantify and compare 141 
the results in an easy and reliable way, the number of peroxisomes in each transfected cell 142 
was counted and catalogued as more than 50 (no or moderate reduction in peroxisome 143 
number), between 1 and 50 (strong reduction in peroxisome number), or none (complete 144 
absence of peroxisomes). 145 
A first set of experiments, in which peroxisome number was analyzed with 146 
ABCD3/PMP70-antibodies (Fig. 2A), revealed that (i) also PEX5(S)-EGFP—but not EGFP-147 
PEX5(S) or PEX5(S)-FLAG—could trigger peroxisome removal, (ii) the PEX5-EGFP-148 
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mediated removal process of peroxisomes was PEX5 splice-variant independent, and (iii) this 149 
process could be triggered by both human and mouse PEX5(L) (Fig. 2B). Co-expression of 150 
mt-EGFP had no effect on the outcome of the experiment (Fig. S1). To eliminate the 151 
possibilities that overexpression of PEX5-EGFP resulted in the masking of the PEX14 and 152 
ABCD3 epitopes or the selective degradation of these PMPs, we also carried out 153 
immunostainings with antibodies recognizing either CAT/catalase or a mix of peroxisomal 154 
matrix proteins (ab-MF16). The results of these experiments clearly showed that also 155 
peroxisomal matrix proteins disappeared upon PEX5(L)-EGFP expression (Fig. S2), thereby 156 
confirming and extending our initial observations. 157 
In a subsequent series of experiments, we obtained evidence that the degree of 158 
peroxisome removal could be correlated with the expression levels of PEX5-EGFP (Fig. S3) 159 
and that this process steadily increased up to 20 h post-transfection, after which no further 160 
increase was observed (Fig. S4). Finally, as KR is a dimeric protein and EGFP has a weak 161 
tendency to dimerize,43 we also checked the peroxisome removal capacity of PEX5-mCherry 162 
and PEX5-HaloTag (mCherry and HaloTag tags are strictly monomeric tags) and observed 163 
that also these PEX5-fusion proteins could induce peroxisome removal (Fig. S5). Taken 164 
together, these data clearly show that the presence of a bulky tag at the C terminus of PEX5 165 
can trigger peroxisome degradation in SV40T-MEFs in a time- and expression level-166 
dependent manner. 167 
PEX5-EGFP-induced peroxisome removal is dependent on autophagy 168 
As autophagy is thought to be the responsible mechanism for most, if not all, 169 
peroxisome turnover in mammalian cells,29,31 we next investigated the potential involvement 170 
of this pathway in PEX5-EGFP-mediated peroxisome degradation. For this purpose, we 171 
employed SV40 large T antigen-transformed atg5-/- MEFs as well as control MEFs treated 172 
with the autophagy inhibitors 3-methyladenine (3-MA) or LY294002: ATG5 is essential for 173 
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efficient MAP1LC3-lipidation, a crucial step in the formation of canonical autophagosomes;44 174 
and 3-MA and LY294002 are inhibitors of class I phosphoinositide 3-kinases and class III 175 
phosphatidylinositol 3-kinases (PtdIns3Ks) that suppress autophagosome formation via 176 
inhibition of the class III enzyme.45 Importantly, as both PtdIns3K inhibitors (Fig. 3A) as well 177 
as ATG5 inactivation (Fig. 3B) interfered with PEX5-EGFP-induced peroxisome removal, 178 
the observed phenotype is highly likely to be autophagy dependent. In this context, it is also 179 
interesting to mention that—despite the fact that peroxisome removal was not completely 180 
blocked in atg5-/- cells—PEX5-EGFP behaved similarly to SLC25A17-Ub, a non-natural 181 
protein already reported to selectively trigger peroxisome removal in mammalian cells in an 182 
autophagy-dependent manner (Fig. 3C).38 Taken together, these data strongly point towards 183 
autophagy as the major mechanism for PEX5-EGFP-induced peroxisome removal. 184 
Nevertheless, and despite repeated efforts, we were unable to colocalize peroxisomes 185 
with endogenous LC3 or LAMP1 (lysosomal-associated membrane protein 1) nor with 186 
recombinant EGFP-LC3, LAMP1-EGFP, or LAMP2A-EGFP, not even in the presence of 187 
chloroquine (a lysosomal lumen alkalizer) or protease inhibitor mixtures of N-(trans-188 
epoxysuccinyl)-L-leucine 4 guanidinobutylamide (E-64), pepstatin A and/or leupeptin (data 189 
not shown). Potential explanations for these negative results may be that the percentage of 190 
(GFP-)LC3 involved in PEX5-EGFP-induced peroxisome removal and the amount of 191 
peroxisomal markers trapped within the lysosomal compartment are simply below the 192 
detection limit. Regarding the latter, it is important to note that, as (i) the peroxisomal volume 193 
in mammalian cells is 1% of the total cellular volume,46 and (ii) the PEX5-EGFP-induced 194 
removal of the peroxisome population was spread over 20 h (Fig. S4), the presence of even a 195 
minor residual protease activity may be sufficient to prevent the detection of peroxisomal 196 
marker proteins in lysosomes. In addition, as even low concentrations of chloroquine (e.g., 20 197 
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µM) cause a dramatic expansion of the lysosomal compartment, signal dilution effects need 198 
also to be taken into account. 199 
To rule out the possibility that the observed decrease in peroxisome number was not a 200 
direct result of high basal turnover rates in combination with a reduction in peroxisome 201 
formation, we also performed a series of pulse-chase labeling experiments to estimate the 202 
basal turnover rate of peroxisomes in SV40T-MEFs (peroxisomes are continually formed and 203 
degraded, and the actual number of these organelles within a cell depends on the kinetics of 204 
both processes). However, as could be expected from similar studies performed in Chinese 205 
hamster ovary cells,47 the basal turnover rate of peroxisomes was not high enough to consider 206 
a reduction in peroxisome formation as the causal factor for the PEX5-EGFP-induced 207 
phenotype (Fig. S6). In this context, it is also worth noting that, under basal conditions, the 208 
number of peroxisomes was not statistically different (p<0.01) between any of the SV40T-209 
MEFs under study (Fig. S7). 210 
Finally, we also investigated whether or not PEX5-EGFP expression activated general 211 
autophagy. As these studies revealed that such expression did not lead to an increase in the 212 
average number of MAP1LC3B puncta per cell (data not shown) or to differences in the 213 
amount of LC3-II between samples in the presence or absence of the vacuolar-type ATPase 214 
inhibitor bafilomycin A1 (Fig. S8; for reasons that will become clear later, PEX5C11A-EGFP 215 
was included as a negative control), PEX5-EGFP expression did not seem to affect the overall 216 
autophagic flux. This idea was further corroborated by the observation that expression of this 217 
protein selectively eliminated peroxisomes and had no effect on the normal distribution and 218 
morphology of the endoplasmic reticulum and mitochondria (Fig. S9). 219 
The N-terminal cysteine residue that marks PEX5 for recycling is crucial for PEX5-220 
EGFP-induced pexophagy 221 
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As (i) it has been hypothesized that ubiquitination of endogenous proteins at the 222 
peroxisomal membrane may trigger peroxisome removal in mammalian cells,30,32,38 and (ii) 223 
PEX5 export requires monoubiquitination of the protein at Cys11,21 we next examined 224 
whether or not 2 N-terminally truncated (PEX5(S)∆N16 and PEX5(S)∆N110) variants of PEX5 225 
lacking this cysteine residue could still induce peroxisome degradation. Since these 226 
experiments clearly showed that a deletion of the first 16 amino acid residues in PEX5 is 227 
sufficient to disrupt PEX5-EGFP-induced peroxisome removal (Fig. 4A), we performed 228 
another series of experiments in which we tested the capability of PEX5(L)C11K-EGFP, 229 
PEX5(L)C11S, PEX5(L)C11S-EGFP, PEX5(L)C11A, and PEX5(L)C11A-EGFP to trigger 230 
peroxisome removal. Note that (i) PEX5(L)C11K is a monoubiquitinatable and fully functional 231 
variant of PEX5 in which Cys11 has been substituted by a lysine,48 (ii) PEX5(L)C11S is an 232 
export-incompetent PEX5 mutant in which Cys11 has been replaced by a serine, an amino 233 
acid residue that can be slowly ubiquitinated under specific conditions,49,50 and (iii) 234 
PEX5(L)C11A is also an export-incompetent PEX5 mutant in which Cys11 has been exchanged 235 
for an alanine, a nonubiquitinatable amino acid.48,51 As shown in Fig. 4B, expression of 236 
PEX5(L)C11K-EGFP, PEX5(L)C11S-EGFP, and PEX5(L)C11A-EGFP respectively caused a 237 
strong, moderate, or no pexophagy phenotype in most transfected cells, strongly indicating 238 
that the presence of a ubiquitinatable residue at amino acid position 11 of PEX5 is crucial for 239 
PEX5-EGFP-induced peroxisome removal. Note that further analysis of the key variants of 240 
PEX5-EGFP demonstrated that these proteins were all partially localized to peroxisomes (Fig. 241 
S10) and expressed to a similar extent (Fig. S11). Interestingly, expression of nontagged 242 
PEX5(L)C11S, but not PEX5(L)C11A, also triggered peroxisome degradation in a small number 243 
of cells (Fig. 4B). Although the reason for this phenomenon is not yet clear (but see 244 
Discussion), this result further supports the importance of a ubiquitinatable residue at amino 245 
acid position 11 of PEX5 to trigger peroxisome removal. 246 
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Finally, we also tested the ability of PEX5(L)N526K-EGFP, PEX5(L)K527R-EGFP, and 247 
PEX5(S)∆C299-PEX5(L)/PEX5R∆N326-EGFP to induce peroxisome removal in our 248 
experimental setup. PEX5(L)N526K and PEX5(L)K527R are PEX5 mutants that are incapable of 249 
binding PTS1 proteins or undergo lysine-linked monoubiquitination, respectively,17,40 and 250 
PEX5(S)∆C299-PEX5L/PEX5R∆N324-EGFP is a chimeric protein composed of the N-terminal 251 
298 amino acids of PEX5(S) and the C-terminal TPR-containing domain (amino acids 325 to 252 
624) of PEX5L/PEX5R (peroxisomal biogenesis factor 5-like), a PEX5-related PTS1-binding 253 
protein.52 As the PEX5(L)N526K and PEX5(L)K527R mutants did not lose their capacity to 254 
trigger PEX5-mediated peroxisome degradation (Fig. 4C), it can be concluded that neither 255 
PTS1 binding nor monoubiquitination of PEX5(L) at Lys527 were essential for this process. 256 
In addition, from the results obtained with the chimeric PEX5(S)∆C299-PEX5L/PEX5R∆N326-257 
EGFP protein (Fig. 4C), it was clear that—although the primary amino acid sequence of the 258 
TPRs clearly influenced the peroxisome removal phenotype—the TPRs of PEX5 were not 259 
essential for PEX5-EGFP-triggered peroxisome removal. In summary, these data provide 260 
direct evidence that the N-terminal cysteine residue that marks PEX5 for recycling is crucial 261 
for PEX5-mediated peroxisome removal. 262 
C-terminal tagging with EGFP renders PEX5 export-incompetent and leads to the 263 
accumulation of Ub-PEX5-EGFP at the peroxisomal membrane 264 
As previous work has pointed out that (i) the accumulation of monoubiquitinated 265 
membrane proteins on the cytosolic surface of peroxisomes can cause pexophagy,38,39 and (ii) 266 
Cys11-ubiquitination of PEX5 regulates its ATP-dependent export from peroxisomes back to 267 
the cytosol,21,51 we here investigated the dynamics and topology of PEX5(L)-EGFP at the 268 
peroxisomal membrane by employing a previously described in vitro import/export assay.21 In 269 
short, we incubated radiolabeled PEX5(L), PEX5(L)-EGFP, PEX5(L)C11S-EGFP, and 270 
PEX5(L)C11A-EGFP with a (peroxisome-containing) rat liver postnuclear supernatant fraction 271 
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supplemented with ATP or AMP-PNP and either Ub or GST-Ub. Organelle and/or 272 
supernatant fractions were then treated or not with proteinase K, processed for SDS-PAGE 273 
under nonreducing or reducing conditions, and assayed by autoradiography. Recall that (i) 274 
during its transient passage through the peroxisomal membrane, PEX5 adopts a 275 
transmembrane topology, only exposing a protease-accessible N-terminal domain of 276 
approximately 2 kDa to the cytosol, (ii) monoubiquitination of PEX5 exclusively occurs when 277 
the receptor is embedded in the DTM, (iii) substitution of Cys11 by Ser or Ala results in 278 
PEX5 proteins that are still functional in docking and membrane insertion but are largely or 279 
completely incompetent in the ubiquitination/export process, respectively, and (iv) AMP-280 
PNP, a nonhydrolyzable analog of ATP, blocks the export of monoubiquitinated PEX5 back 281 
into the cytosol.48,53 282 
In a first series of experiments, we found that PEX5(L)-EGFP entered the DTM and 283 
became monoubiquitinated similar to nontagged PEX5(L) (Fig. 5A, left panels, compare the 284 
AMP-PNP conditions). However, we also observed that Ub-PEX5(L)-EGFP, in contrast to 285 
Ub-PEX5(L), encountered difficulties in leaving the DTM (same panels, compare the ATP 286 
conditions), a property that can be better appreciated using a 2-step import/export assay (Fig. 287 
5B). In these assays, radiolabeled PEX5(L) and PEX5(L)-EGFP were first imported in the 288 
presence of AMP-PNP. The organelles were then sedimented and the supernatant fraction 289 
(containing nonimported PEX5 proteins) was discarded. Finally, the organelles were 290 
resuspended in fresh ATP-containing import buffer and incubated for 5 min at 37°C to 291 
promote export of the monoubiquitinated species. As shown in Fig. 5B, the vast majority of 292 
monoubiquitinated PEX5(L)-EGFP remained in the organelle fraction, in contrast to 293 
PEX5(L), which was recovered mainly in the soluble fraction. PEX5(L)C11S-EGFP and 294 
PEX5(L)C11A-EGFP could also efficiently enter the DTM (Fig. 5A, right panels). Nonetheless, 295 
as these molecules are respectively poor substrates or not substrates for monoubiquitination, 296 
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they became trapped at the DTM, even in the presence of ATP. Note that, as (i) PEX5(L)C11S-297 
EGFP and PEX5(L)C11A-EGFP were not posttranslationally modified at the peroxisomal 298 
membrane (Fig. 5A, right panels), (ii) replacement of Ub with GST-Ub resulted in higher 299 
molecular weight species of PEX5(L) and PEX5(L)-EGFP (Fig. 5C, upper panels), and (iii) 300 
treatment of the protein samples with DTT destroyed the thioester bond between (GST-)Ub 301 
and PEX5(L)(-EGFP) (Fig. 5C, lower panels; see also Fig. S12), it is clear that the PEX5(L) 302 
modifications in our assays represent Cys11-dependent monoubiquitination events. 303 
In a second series of experiments, we found that organelle-bound (Ub-)PEX5(L) and 304 
(Ub-)PEX5(L)-EGFP displayed a similar topology, as assessed by protease-protection assays. 305 
Indeed, in the presence of ATP or AMP-PNP, we respectively detected (i) small amounts of 306 
PEX5(L) and PEX5(L)-EGFP exposing the majority of their mass in the peroxisomal matrix 307 
(Fig. 6, upper panel, lanes 2 and 5, arrowheads labeled ‘a’), and (ii) large amounts of DTM-308 
embedded Ub-PEX5(L) and Ub-PEX5(L)-EGFP (Fig 6, upper panel, lanes 3 and 6, 309 
arrowheads labeled ‘b’). At first sight, this finding may be counterintuitive given our earlier 310 
observation that, in the presence of ATP, Ub-PEX5(L)-EGFP was more abundant in the 311 
organellar fraction than Ub-PEX5(L) (Fig. 5A, compare lane 2 in the 2 upper panels). 312 
However, a careful analysis of the autoradiographs that are shown in Fig. 6 revealed that a 313 
major fraction of Ub-PEX5(L)-EGFP obtained in the presence of ATP was accessible to 314 
proteinase K, whereas the one obtained in the presence of AMP-PNP was not. Indeed, in the 315 
condition with ATP, we observed 3 additional protease-resistant PEX5(L)-EGFP fragments 316 
around 35 kDa (Fig. 6, see asterisks). Note that these fragments contained the EGFP moiety 317 
of the chimeric protein because they were recognized by an anti-EGFP antibody (see Fig. 318 
S13). In addition, as they could not be observed for export-incompetent PEX5(L)C11A-EGFP 319 
(Fig. 6, upper and lower panels, 2 last lanes), our findings strongly indicate that the REM is 320 
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capable of extracting PEX5-EGFP partially out of the DTM, but most likely becomes jammed 321 
when it encounters a tightly folded domain (e.g., EGFP or KR). 322 
PEX5-EGFP is monoubiquitinated in cellulo in a Cys11-dependent manner 323 
To find evidence that PEX5-EGFP is also monoubiquitinated at Cys11 when 324 
expressed in SV40T-MEFs, whole lysates of cells expressing PEX5C11A-EGFP or PEX5-325 
EGFP were subjected to SDS-PAGE under nonreducing and reducing conditions and 326 
processed for immunoblotting with antibodies against PEX5. From these experiments, it is 327 
clear that a small portion of PEX5-EGFP was posttranslationally modified upon expression in 328 
these cells (Fig. S14). In addition, as (i) this modification is Cys11-dependent, DTT-sensitive, 329 
and caused a molecular shift of approximately 8 kDa (Fig. S14), (ii) this behavior mimics that 330 
of PEX5-EGFP in vitro (Figs. 5 and S12), and (iii) previous studies have shown that, in 331 
mammals, the DTT-sensitive form (with monoubiquitination at the conserved cysteine 332 
residue) is associated with peroxisomes and the DTT-insensitive form (with unknown 333 
modification) is located in the cytosol,40,48;51,54 it is reasonable to conclude that the 334 
posttranslationally-modified form of PEX5-EGFP represents peroxisome-associated 335 
ubiquitinated PEX5-EGFP. 336 
Next, as expression of PEX5-EGFP is expected to lead to an accumulation of Ub-337 
PEX5-EGFP at the peroxisomal membrane, we also checked whether or not PEX5-EGFP-338 
expressing cells contain ubiquitin-positive peroxisomes. Unfortunately, despite the fact that 339 
we used 2 different anti-ubiquitin antibodies, including one that was already successfully used 340 
by others to visualize ubiquitin-positive peroxisome clusters in PEX3-HA2-overexpressing 341 
cells,32 no ubiquitin-positive peroxisomes could be detected, not even upon treatment of the 342 
cells with 3-MA (data not shown). However, (i) the ubiquitin-moieties in DTM-embedded 343 
PEX5-EGFP molecules may be shielded by potential interaction partners (e.g., PEX1, or 344 
PEX6), (ii) in contrast to what happens in PEX3-HA2 overexpressing cells, the fluorescence 345 
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intensity of putative ubiquitin-positive peroxisomes is not enhanced because the organelles do 346 
not cluster upon expression of PEX5-EGFP, and (iii) ubiquitin is also ligated to a great 347 
number of endogenous proteins, the threshold for detection of ubiquitin-positive peroxisomes 348 
may be below the limit needed to visualize such structures above background fluorescence. 349 
The PEX5-EGFP-induced phenotype is cell type-specific 350 
We also expressed PEX5-EGFP in other mammalian cell types (e.g., human skin 351 
fibroblasts, rat embryonic fibroblasts, and a mouse oligodendrocyte cell line) and 352 
unexpectedly found that this protein could not trigger peroxisome removal in these cells (data 353 
not shown). In addition, we obtained empirical evidence that the PEX5-EGFP-induced 354 
peroxisome removal phenotype in MEFs can be directly linked to the SV40 large T antigen-355 
induced immortalization of these cells. Indeed, expression of PEX5-EGFP quickly resulted in 356 
the disappearance of peroxisomes in SV40T-cells (e.g., “homemade” control MEFs,55 Atg5+/+ 357 
MEFs,56 and Perk+/+ MEFs,57), but not in primary control MEFs (passage <5)55 and 358 
spontaneously transformed Sqstm1+/+ MEFs.58 Note that, as the expression levels of pEGFP-359 
N1-encoded proteins are comparable in spontaneously transformed- and SV40T-cells, at least 360 
within the time scale of the experiments (Fig. S15), these differences in phenotype are caused 361 
by other factors than differences in PEX5-EGFP expression levels (see Discussion). 362 
We still considered the possibility that PEX5-EGFP displays an export defect in vivo 363 
only in SV40T-cells and that the protein is actually functional in other cells. To test this 364 
possibility, PEX5-deficient human fibroblasts and spontaneously-transformed MEFs were 365 
subjected to transfection experiments to assess whether or not PEX5-EGFP has 366 
complementing or dominant-negative activity in peroxisomal matrix protein import. 367 
Appropriate controls (non-tagged PEX5WT, PEX5C11K, PEX5C11S, and PEX5C11A) were 368 
included to discriminate between different outcomes (PEX5WT and PEX5C11K, but not 369 
PEX5C11S and PEX5C11A, restore PTS1 protein import in PEX5-deficient cells; and PEX5C11S 370 
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and PEX5C11A, but not PEX5WT and PEX5C11K, exert a dominant-negative activity on the 371 
same process in control cells).48,51 From these experiments, it is clear that PEX5(L)-EGFP 372 
cannot restore peroxisomal matrix protein import in PEX5-deficient human fibroblasts (Fig. 373 
S16A) and interfered with PTS1 protein import upon expression in spontaneously 374 
transformed control MEFs (Fig. S16B). 375 
Downregulation of PEX1, SQSTM1, or NBR1 expression does not interfere with PEX5-376 
EGFP-induced peroxisome removal 377 
To investigate the potential role of the PEX5 export machinery in PEX5-EGFP-378 
induced peroxisome removal, we used Dicer substrate RNAs (DsiRNAs) to downregulate the 379 
expression level of PEX1, an essential REM component.16 Note that, under the employed 380 
conditions (for details, see Materials and Methods), virtually all cells were transfected (as 381 
confirmed by a fluorescently-labeled scrambled control RNA duplex) (Fig. S17). Despite the 382 
fact that we could knock down PEX1 (Fig. S18, panels A and B), no effect could be 383 
observed on the level of the PEX5-EGFP-induced phenotype (Fig. 7A). In addition, such 384 
treatment did not affect peroxisome number in cells overexpressing HsPEX5 (Fig. 7B). 385 
Unfortunately, as additional experiments revealed that the residual amounts of PEX1 were 386 
sufficient to retain a functional PTS1 import machinery (Fig. S18C), no reliable conclusions 387 
can be drawn regarding the potential role of PEX1 in the process under study. 388 
To investigate the potential role of the ubiquitin-binding selective autophagy receptors 389 
SQSTM1 and NBR1, a similar approach was used. Also here we could observe a significant 390 
downregulation of the expression levels of SQSTM1 (Fig. S19, panels A and C) and, albeit 391 
to a lesser extent, NBR1 (Fig. S19, panels B and D). Unfortunately, once again, we could not 392 
observe any effect on the level of PEX5-EGFP-induced peroxisome removal (Fig. 7C). The 393 
interpretation of these data is presented below. 394 
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Discussion 395 
In recent years, the phenomenon of selective organelle degradation has attracted 396 
increasing attention.59-61 The main reason for this is that an accumulation of dysfunctional 397 
organelles contributes to developmental abnormalities, aging, inflammation, cancer and other 398 
diseases.6 The pexophagy field has also gained much interest. However, despite rapid and 399 
considerable progress in our understanding of how peroxisomes are selectively degraded in 400 
(Saccharomyces cerevisiae and methylotrophic) yeasts,29,62-65 little is known about how this 401 
process is regulated in mammalian cells.31 This is perhaps best illustrated by the fact that, 402 
although it has been demonstrated that ectopic expression of PMPs attached to cytosolically 403 
exposed ubiquitin can trigger pexophagy,38 endogenous PMPs that are ubiquitinated during 404 
pexophagy have not yet been identified. In this study, we show that expression of a 405 
monoubiquitinatable but export-incompetent variant of PEX5, a naturally monoubiquitinated 406 
protein, results in the accumulation of Ub-PEX5 at the peroxisomal membrane and triggers 407 
peroxisome removal in SV40T-MEFs. These observations provide the first strong evidence in 408 
favor of the recent hypothesis that alterations in PEX5 and ubiquitin dynamics on peroxisome 409 
membranes can regulate mammalian pexophagy.30,39 The potential underlying molecular 410 
mechanisms of these findings and their implications for future research are discussed in the 411 
following paragraphs. 412 
In our initial experiments aimed at clarifying whether or not peroxisomes can be 413 
selectively removed upon oxidative damage, we accidentally found that expression of PEX5 414 
proteins fused to a bulky C-terminal tag (e.g., KR, EGFP, HaloTag, or mCherry) caused the 415 
disappearance of peroxisomes in SV40T-MEFs (Figs. 1A, 2B, and S5). In addition, we 416 
observed that this process required the presence of the N-terminal cysteine residue that marks 417 
PEX5 for recycling (Fig. 4B). As these observations, combined with the finding that PEX5 418 
Cys11 monoubiquitination only takes place at the peroxisomal membrane,21 strongly 419 
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indicated that the addition of a bulky tag to the C terminus of PEX5 interferes with the export 420 
step of the cycling receptor from the peroxisome to the cytosol, we employed a previously 421 
established in vitro assay21 to study the import/export kinetics of PEX5-EGFP at the 422 
peroxisomal membrane. These experiments clearly demonstrated that PEX5-EGFP can enter 423 
the DTM and become monoubiquitinated at Cys11 as is the nontagged wild-type PEX5 (Fig. 424 
5). However, in contrast to Ub-PEX5, Ub-PEX5-EGFP remained largely associated with the 425 
organelle pellet in the presence of ATP (Fig. 5A, B), clearly showing that the existence of a 426 
tightly folded domain at the C terminus of PEX5 interfered with its export back into the 427 
cytosol (Fig. 5A, B). Importantly, Ub-PEX5-EGFP was still a substrate for the REM. Indeed, 428 
this protein became partially accessible to proteinase K under conditions where the REM was 429 
active (i.e., when ATP but not AMP-PNP was used in the in vitro assays) yielding a set of 430 
organelle-associated protease-resistant fragments of approximately 35 kDa that comprise the 431 
bulky EGFP moiety (Figs. 6 and S13). The behavior of Ub-PEX5-EGFP can be explained in 432 
2 ways. On the one hand, it is possible that PEX5 exits the DTM via a REM-dependent 433 
threading mechanism, and that—by analogy to some other AAA+ ATPases66—tightly folded 434 
proteins such as EGFP (or a cargo protein that cannot be released from PEX5) cannot pass 435 
through a hole that may be present in the PEX1-PEX6 complex. Alternatively, it is 436 
conceivable that the DTM acts as a trap for globular proteins, letting them in but preventing 437 
them from getting out. Regardless of the mechanism, and although there is currently 438 
compelling evidence suggesting that the cargo release step occurs prior to monoubiquitination 439 
of PEX5,19,67,68 the results presented here provide experimental evidence to support the 440 
concept that the peroxisomal export machinery may also participate in cargo release.69 441 
According to this idea, the ATP used by the REM to extract Ub-PEX5 from the DTM could 442 
also provide the energy necessary to disrupt the PEX5-cargo protein interaction, e.g., by 443 
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unfolding the PTS1-binding domain of PEX5. Further data are necessary to clarify these 444 
important mechanistic aspects of the peroxisomal protein import machinery. 445 
As it is well-known that the insertion of PEX5 into the peroxisomal membrane is a 446 
cargo-dependent process,69 the observation that both PEX5(L)N526K–EGFP and PEX5(S)∆C299-447 
PEX5L/PEX5R∆N324-EGFP trigger peroxisome removal may be difficult to reconcile with the 448 
suggested model that ubiquitinated versions of these proteins accumulate at the peroxisomal 449 
membrane. However, here it is important to mention that (i) the N526K mutation in PEX5(L) 450 
(and the corresponding N489K mutation in PEX5(S)) causes conformational alterations at the 451 
N-terminal half of PEX5 mimicking the ones induced by binding of a PTS1-containing 452 
peptide to the normal peroxin,49 and (ii) also C-terminally truncated versions of PEX5 have 453 
been reported to function as substrates for the peroxisomal DTM.71 In this context, it is 454 
interesting to mention that also PEX5(S)N489K-EGFP, a version of PEX5 that lacks both its 455 
PTS1 and PEX7-binding sites, can trigger peroxisome removal in SV40T-MEFs (data not 456 
shown). Another intriguing observation is that non-tagged PEX5C11S, but not PEX5C11A, 457 
triggered peroxisome removal in a small number of cells (Fig. 4B). Although PEX5C11S can 458 
be monoubiquitinated at the DTM,21 this process occurs at a very slow rate explaining why 459 
this protein accumulates at the peroxisome. While further data are necessary to explain the 460 
peroxisome removal phenotype induced by PEX5C11S, it is tempting to speculate that PEX5 461 
molecules retained for a long time at the peroxisomal membrane (e.g., in case the cargo 462 
protein cannot be released from PEX5) become strongly (or even covalently) linked to some 463 
DTM component(s) (e.g., by ROS-promoted mechanisms). In such a scenario, the subsequent 464 
monoubiquitination of these molecules would trigger their REM-dependent extraction from 465 
the DTM. However, this process would not be completed due to the strong PEX5-DTM 466 
interaction, thus leading to the accumulation of partially exposed Ub-PEX5C11S species at the 467 
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peroxisome limiting membrane, similar to the ubiquitinatable PEX5-EGFP species used in 468 
this work. 469 
As our data indicate that the addition of a bulky tag to the C terminus of PEX5 can 470 
result in the accumulation of partially extracted Ub-PEX5 on the peroxisomal surface, it is 471 
conceivable to envisage that this will eventually result in the recruitment of the autophagic 472 
machinery to the organelle. However, despite the fact that PEX5-mediated peroxisome 473 
removal depends on ATG5 and can be blocked by 3-MA and LY294002 (Fig. 3), we were 474 
repeatedly unable to colocalize peroxisomes with EGFP-MAP1LC3B, even when culturing 475 
the cells in medium supplemented with bafilomycin A1 (Fig. S20) or chloroquine (data not 476 
shown). Nevertheless, here it should be mentioned that such colocalization could easily be 477 
observed upon expression of SLC25A17-Ub, even in the absence of autophagy inhibitors 478 
(Fig. S20, upper panels). In addition, unlike SLC25A17-Ub-, NBR1-, or PEX3-induced 479 
pexophagy, where peroxisomes cluster prior to degradation,30,32,38 we did not observe any 480 
clustering of peroxisomes upon PEX5-KR expression (Fig. S20, compare the upper and lower 481 
panels). Note that this may also impede the likeliness of finding peroxisomes within 482 
autophagosomes, which have an approximate half-life of only 10 min.44 483 
Regarding the observations that (i) the PEX5-EGFP-induced peroxisome removal 484 
phenotype in MEFs can be directly linked to the SV40 large T antigen-induced 485 
immortalization of these cells (data not shown), and (ii) SV40 large T antigen does not 486 
directly influence the expression levels of PEX5-EGFP (Fig. S15), it is important to note that 487 
SV40T-cells display cell type-specific global changes in gene expression (including some 488 
components of the cellular ubiquitination/deubiquitination machinery).72,73 These 489 
observations suggest that the PEX5-EGFP-induced phenotype depends on a critical balance of 490 
multiple factors that remain to be determined and may even be cell type-specific (e.g., the 491 
promptness with which the Ub-moiety is recognized by the pexophagy machinery, the amount 492 
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of ubiquitin at the peroxisomal membrane, the kinetics of PEX5 493 
ubiquitination/deubiquitination, and other potential quality control mechanisms, such as 494 
proteasomal removal of [poly]ubiquitinated PEX5). For example, although PEX5 495 
accumulates at the peroxisomal membrane in aging human fibroblasts, the number of 496 
peroxisomes in these cells is profoundly increased.74 However, here it is important to know 497 
that (i) cellular aging is associated with an increase in the GSSG (oxidized glutathione)/GSH 498 
(reduced glutathione) ratio,75 and (ii) exposure of human PEX5 to GSSG results in a 499 
ubiquitination-deficient PEX5 molecule.76 500 
In conclusion, this work presents the first experimental evidence that addition of a 501 
bulky tag to the C terminus of PEX5 interferes with the export of monoubiquitinated PEX5 502 
from the DTM, and that this in turn can trigger peroxisome removal in SV40T-MEFs. These 503 
findings strongly support the idea that peroxisome-associated monoubiquitinated PEX5 may 504 
act as a key surveillance factor for the selective removal of dysfunctional peroxisomes in 505 
mammalian cells.30,39 In this context, we hypothesize that the bulky tag may mimic a cargo 506 
protein that cannot be released from PEX5. However, as the study of mammalian pexophagy 507 
is still in its infancy, this and many other intriguing questions remain. For example, like in 508 
other studies that applied ectopic expression of ubiquitinated PMPs or PEX3 as a pexophagy 509 
trigger,30,32 PEX5-EGFP-induced pexophagy could only be partially blocked in conditions in 510 
which macroautophagy was inhibited. Although this finding may suggest that some 511 
peroxisomes can be removed by alternative degradation pathways,77,78 this needs further 512 
investigation. Also the potential involvement of the PEX5 export machinery, the specific 513 
autophagy receptor proteins (e.g., SQSTM1, NBR1, OPTN, CALCOCO2, HDAC6, etc.), and 514 
the mammalian Atg8 orthologs (i.e., the MAP1LC3 and GABARAP subfamilies)79 need 515 
further investigation. Indeed, as we currently cannot exclude the possibility that—upon 516 
siRNA knockdown—the remaining amounts of PEX1, SQSTM1, or NBR1 are still sufficient 517 
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to sustain PEX5-EGFP-mediated peroxisome removal, the role of these proteins in this 518 
process should ideally be studied in SV40T-knockout cell lines (and that are currently not 519 
available). However, in case the triggering factor for peroxisome removal is not accumulation 520 
of Ub-PEX5 at the DTM but rather accumulation of a partially dislocated Ub-PEX5 at the 521 
DTM/REM, a complete inactivation of PEX1 would not result in an enhanced peroxisome 522 
removal phenotype. Also, in the absence of a functional PEX5 export machinery, a ubiquitin-523 
dependent quality control pathway—called RADAR (receptor accumulation and degradation 524 
in the absence of recycling)80—may be activated (assuming there is one in mammalian cells) 525 
thereby leaving peroxisomes intact. Finally, it is also not yet clear why overexpression of 526 
SLC25A17-Ub, NBR1, or PEX3 induces peroxisomal clustering,30,32,38 whereas we do not 527 
observe this phenotype during PEX5-EGFP-triggered pexophagy. Here it is tempting to 528 
speculate that the clustering phenotype may represent a situation in which excessive 529 
peroxisomes are massively removed, while the mechanism underlying PEX5-EGFP-induced 530 
pexophagy may mimic a condition where dysfunctional organelles are individually degraded. 531 
Also, given that SQSTM1 and NBR1 play a role in PMP-Ub- and PEX3-induced peroxisome 532 
clustering and that this event precedes their targeting to autophagosomes and lysosomes,30,32 it 533 
may well be that SQSTM1 and/or NBR1 are not involved in PEX5-EGFP-induced 534 
peroxisome removal. 535 
In summary, this study provides strong evidence that monoubiquitinated PEX5 can 536 
serve as a quality control mechanism to eliminate peroxisomes. In addition, it paves the way 537 
for further investigations aimed at elucidating the molecular basis underlying peroxisome 538 
degradation in mammalian cells, an essential prerequisite to understand how defects in this 539 
process may be linked to clinically relevant disease phenotypes. 540 
Materials and methods 541 
DNA manipulations and plasmids 542 
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Polymerase chain reactions were routinely performed using Pfx DNA polymerase 543 
(Invitrogen, 11708039). Oligonucleotides and RNAi duplex oligonucleotides used in this 544 
study were synthesized by Integrated DNA Technologies and are listed in Tables S1 and S2, 545 
respectively. The Escherichia coli strain TOP10F’ (Invitrogen, C3030-03) was used for all 546 
DNA manipulations. Restriction enzymes were purchased from TaKaRa. The mammalian 547 
expression vectors pEGFP-N1, pCMV-Tag 2B, pKillerRed-dMito, and pHT2 were 548 
commercially obtained from Clontech (6085-1), Stratagene (211172), Evrogen (FP964), and 549 
Promega (G8241), respectively. A detailed description of the non-commercial plasmids used 550 
in this study is available in the supplementary information (Materials S1). All new plasmids 551 
were verified by DNA sequencing (LGC Genomics). 552 
Cell culture, immunofluorescence and live-cell microscopy 553 
SV40 large T-antigen transformed Atg5+/+, atg5-/-, and Perk+/+ MEFs were kindly 554 
provided by Dr. P. Agostinis (KU Leuven, Belgium).56,57 PEX5-/- human fibroblasts, 555 
spontaneously transformed Sqstm1+/+ MEFs, and the murine oligodendrocyte cell line (158N) 556 
were generous gifts from Dr. G. Dodt (University of Tübingen, Germany), Dr. T. Yanagawa 557 
(Niigata University, Japan), and Dr. S. Ghandour (University of Strasbourg, France), 558 
respectively.58,76,81 Control primary MEFs (C57BL/6) and rat embryonic fibroblasts (Sprague-559 
Dawley) were generated as before.76 All cells were cultured at 37°C in a humidified 5% CO2 560 
incubator in minimum essential medium Eagle α (Lonza, BE12-169F) supplemented with 561 
10% (v/v) fetal bovine serum superior (Biochrom AG, BCHRS0615), 2 mM Ultraglutamine-1 562 
(Lonza, BE17-605E/U1/12), and 0.2% (v/v) Mycozap (Lonza, VZA-2012). MEFs were 563 
transfected using Invitrogen´s Neon Transfection System (1350 V, 30 ms pulse width, 1 564 
pulse).82 To knock down the expression of target genes, the cells were first electroporated 565 
with the appropriate Dicer-substrate RNAs (DsiRNAs), and—2 d later—co-electroporated 566 
with the same DsiRNAs and the plasmid encoding the protein under study. The final 567 
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concentrations in the 10-µl microporator tip were 2 µM for individual DsiRNAs; 0.66 µM per 568 
DsiRNA for TriFECTa RNAi kit duplex combinations, and 1 µg of plasmid. The transfected 569 
cells were either processed for indirect immunofluorescence or lysed for SDS-PAGE and 570 
immunoblot analysis (for sample analysis under nonreducing conditions, cell pellets were first 571 
treated with 10 mM N-ethylmaleimide (NEM; Across Organics, 156100100) to block 572 
deubiquitinases and any endogenous nucleophilic groups that may attack the Ub-PEX5-EGFP 573 
thioester). Samples for immunofluorescence microscopy were fixed and processed as 574 
described before.47 The rabbit polyclonal antiserum against human PEX14,83 the mouse 575 
polyclonal antiserum against bovine CAT/catalase84 and the antibodies raised against a 576 
mixture of peroxisomal matrix proteins (ab-MF16)85 have been described elsewhere. DAPI 577 
(Roche, 10236276001), Hoechst 33258 (Sigma, 14530), the rabbit anti-ABCD3 antibodies 578 
(Sigma, P0497), the mouse anti-FLAG antibodies (Stratagene, 200472-21), the rabbit anti-579 
HaloTag antibodies (Promega, G9281), the mouse anti-LAMP1 antibodies (BD Pharmingen, 580 
553792), the rabbit (Cell Signaling Technology, 2775) and mouse (Nanotools, 0231-581 
100/LC3-5F10) anti-LC3B antibodies, the rabbit (Proteintech, 16004-1-AP) and mouse 582 
(Abcam, ab55474) anti-NBR1 antibodies, the rabbit anti-PEX1 antibodies (Bio-Connect, 583 
13669-1-AP), the rabbit anti-SQSTM1 antibodies (Sigma, P0067), the rabbit anti-ubiquitin 584 
antibodies (Cell Signaling Technology, 3933), the mouse anti-mono/polyubiquitin 585 
monoclonal antibody (Enzo, FK2, BML-PW8810), the Alexa Fluor 350- (Invitrogen, 586 
A11069), Alexa Fluor 488- (Invitrogen, A11017 and A11070) or Texas Red- (TxRed; 587 
Calbiochem, 401355 and 401230) conjugated secondary antibodies were commercially 588 
obtained. To interfere with the autophagic process, the cells were cultivated in the presence of 589 
10 mM 3-MA (Sigma, M9281), 100 nM bafilomycin A1 (Sigma, B1793), 10 µM LY294002 590 
(Sigma, L-9908), 20 µM chloroquine (Sigma, C6628), 10 µM E-64 (MP Biomedicals, 591 
152846), 10 µM pepstatin A (Sigma, P-4265), and/or 100 µM leupeptin hemisulfate (Fluka, 592 
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62070). Cells for live-cell imaging were seeded and imaged in FluoroDish cell culture dishes 593 
(World Precision Instruments, FD35-100). Where indicated, cells were treated for 1 h with 594 
500 nM MitoTracker® Red CM-H2Xros (Life Technologies, M7513) or ER-Tracker
TM Blue-595 
White DPX (Life Technologies, E-12253) in regular cell culture medium, and washed once 596 
with the same medium immediately before imaging. The sequential labeling of live cells 597 
expressing HaloTag-HsHAO2 (hydroxyacid oxidase 2 [long chain]) was done for the 598 
specified period of time with 250 nM HaloTag TMR (Promega, G8251) and 10 nM HaloTag 599 
R110Direct (Promega, G3221) ligands as described elsewhere.86 After the first and second 600 
labeling reactions, the cells were washed 6 times and once, respectively, with standard growth 601 
medium. Fluorescence was evaluated on a motorized inverted IX-81 microscope (Olympus), 602 
controlled by Cell-M software (Olympus) and equipped with a temperature-, humidity-, and 603 
CO2-controlled incubation chamber. The technical specifications of the objectives, excitation 604 
and emission filters, and digital camera have been described elsewhere.42 The Cell-M 605 
software was used for quantitative image analysis. 606 
In vitro import/export assays 607 
Rat liver postnuclear supernatant (PNS) for in vitro assays was prepared in SEM 608 
buffer (0.25 M sucrose, 20 mM MOPS-KOH, pH 7.2, 1 mM EDTA-NaOH, pH 7.2) 609 
supplemented with 2 µg/ml E-64 (Sigma, E3132), as described before.70 [35S]-labeled proteins 610 
were synthesized in vitro using the TNT® T7 Quick Coupled Transcription/Translation 611 
System (Promega, L1170) in the presence of [35S]methionine (specific activity >1000 612 
Ci/mmol; PerkinElmer Life Sciences, NEG709A001MC). In the in vitro import reactions 613 
(100 µl final volume), 1 µl of the relevant 35S-labeled protein was added to 600 µg of PNS 614 
protein that had been primed for import (incubation for 5 min at 37ºC in import buffer (0.25 615 
M sucrose, 50 mM KCl, 20 mM MOPS-KOH, pH 7.2, 3 mM MgCl2, 20 µM methionine, and 616 
2 µg/ml E-64) containing 0.3 mM ATP (Sigma, A2383).22,67 Import assays also contained 2 617 
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mM glutathione (Sigma, G4251), 3 μM ubiquitin aldehyde53 and, where indicated, ATP (3 618 
mM), AMP-PNP (3 mM; Sigma, A2647), bovine ubiquitin (15 μM; Sigma, U6253) or GST-619 
Ub21 (15 μM). After incubation for 30 min at 37°C, samples were treated with 20 mM NEM 620 
(Sigma, E3876) on ice for 5 min, as described before.48 To separate organelles from soluble 621 
proteins, the in vitro import reactions were diluted with ice-cold SEMK buffer (SEM buffer 622 
containing 80 mM KCl) and centrifuged at 16,000 x g for 20 min at 4°C. Samples were 623 
subjected to trichloroacetic acid precipitation and processed for SDS-PAGE under reducing or 624 
nonreducing conditions, as specified. Protease protection assays were done using proteinase K 625 
(400 μg/ml final concentration; Sigma, P2308) for 40 min on ice.53 The 2-step in vitro 626 
import/export assay was exactly done as described before.68 For the immunoprecipitation 627 
assays, protease-treated organelles from import assays were solubilized for 30 min at 4ºC in 628 
immunoprecipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA-NaOH, 629 
pH 8.0, 0.1% [w/v] SDS [Merck, 1137601000], 1% [w/v] Triton X-100 [Sigma, T9284], 630 
0.5% [w/v] sodium deoxycholate [Sigma, D5670], 500 µg/ml phenylmethylsulfonyl fluoride 631 
[Sigma, P7626] and 1/200 [v/v] mammalian protease inhibitor mixture [Sigma, P8346]). After 632 
removing the insoluble material (15 min at 15,000 x g), the supernatant fraction was divided 633 
in 3 aliquots. One aliquot (total) was kept at 4ºC during the complete procedure and then 634 
subjected to trichloroacetic acid precipitation. The other 2 aliquots received 25 μl (bed 635 
volume) of protein A-Sepharose® beads (Sigma, P3391) that were preincubated with either 3 636 
μl of an anti-EGFP serum88 or a control serum, and incubated for 2 h at 4ºC with gentle 637 
shaking. After removing the supernatant fraction, the beads were washed 3 times with 638 
immunoprecipitation buffer and once with 1X phosphate-buffered saline (137 mM NaCl, 2.7 639 
mM KCl, 4.3 mM Na2HPO4, 1.1 mM KH2PO4). Immunoprecipitated proteins were eluted 640 
with 45 µl of Laemmli sample buffer and the corresponding immunodepleted supernatant 641 
fractions were subjected to trichloroacetic acid precipitation. 642 
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Statistical analysis 643 
Stastistics were performed on the VassarStats statistical computation website 644 
(http://vassarstats.net/). A 2-sample t-Test for independent samples was used to analyze the 645 
results. The significance levels were set at p<0.05 (denoted by *) and p<0.01 (denoted by **). 646 
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Figure legends 904 
Figure 1. Expression of PEX5-KR triggers the removal of peroxisomes. SV40T-MEFs were 905 
transfected with plasmids encoding either (A) PEX5(L)-KR, (B) PEX5(L), or (C) KR. One 906 
day later, the cells were fixed, counterstained with DAPI, and processed for 907 
immunofluorescence with anti-PEX5 and/or anti-PEX14 antibodies followed by TxRed- 908 
and/or Alexa Fluor 488-conjugated secondary antibodies. (A) Upper and lower panels show a 909 
transfected cell where all, or most, peroxisomes are absent, respectively. Arrows indicate 910 
some of the remaining peroxisomes. Scale bar: 10 µm. 911 
Figure 2. Expression of PEX5 proteins fused to a bulky C-terminal tag promotes a decrease 912 
in peroxisome number. SV40T-MEFs were cotransfected with plasmids encoding 913 
mitochondria-targeted EGFP (mt-EGFP; green color; marker for transfected cells) and either 914 
HsPEX5(S), HsPEX5(S)-FLAG, EGFP-HsPEX5(S), HsPEX5(S)-EGFP, HsPEX5(L), 915 
HsPEX5(L)-EGFP, HsPEX5(L)-KR, or mouse (Mus musculus, Mm) PEX5(L)-EGFP. One 916 
day later, the cells were fixed, counterstained with DAPI, and processed for 917 
immunofluorescence with anti-ABCD3 antibodies followed by TxRed- or Alexa Fluor 488-918 
conjugated secondary antibodies. The number of peroxisomes in each transfected cell was 919 
counted and catalogued as more than 50 (>50), between 1 and 50 (1-50), or none (0). (A) 920 
Images of cells co-expressing mt-EGFP and PEX5(S)-EGFP with >50 (left panels), 1-50 921 
(middle panels), or 0 (right panels) remaining peroxisomes are shown (these images depict 922 
representative examples of all phenotypes observed). Scale bar: 10 µm. (B) The percentage of 923 
transfected cells displaying each phenotype is plotted. The values above each bar represent 924 
the number of transfected cells analyzed per condition. A compilation of the results of at least 925 
3 independent experiments (see Fig S21) is shown. The “>50 peroxisomes” values from the 926 
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“HsPEX5(S)” and “HsPEX5(L)” subpanels were statistically compared with the value from 927 
the corresponding control (-) condition (* p<0.05; ** p<0.01). 928 
Figure 3. PEX5-EGFP-induced peroxisome removal is dependent on autophagy. Control 929 
(CT), Atg5+/+ or atg5-/- SV40T-MEFs were co-transfected with plasmids encoding 930 
mitochondria-targeted EGFP (marker for transfected cells) and a plasmid encoding either 931 
PEX5-EGFP or FLAG-SLC25A17-Ub in the absence (-) or presence of 10 mM 3-932 
methyladenine (3-MA) or 10 µM LY294002 (LY). One day later, the cells were fixed and 933 
processed for immunofluorescence with either anti-ABCD3 or anti-PEX14 antibodies. 934 
Peroxisome degradation was quantified and plotted as in Figure 2B. The values above each 935 
bar represent the number of transfected cells analyzed per condition. (A, B) A compilation of 936 
the results of at least 3 independent experiments (see Fig S22) is shown. The “>50 937 
peroxisomes” values from the different (sub)panels were statistically compared with the value 938 
from the corresponding control condition (**, p<0.01). (C) The results of a single experiment 939 
are shown. 940 
Figure 4. The N-terminal cysteine residue that marks PEX5 for recycling is crucial for PEX5-941 
EGFP-induced pexophagy. SV40T-MEFs were cotransfected with plasmids encoding 942 
mitochondria-targeted EGFP (marker for transfected cells) and either (A) full-length 943 
PEX5(S)-EGFP (FL), PEX5(S)∆N16-EGFP (ΔN16), or PEX5(S)∆N110-EGFP (ΔN110), (B) 944 
PEX5(L) (FL), PEX5(L)C11K (C11K), PEX5(L)C11S (C11S), or PEX5(L)C11A (C11A), with or 945 
without a C-terminally fused EGFP-tag, or (C) PEX5(L)-EGFP (FL) PEX5(L)K527R-EGFP 946 
(K527R), PEX5(L)N526K-EGFP (N526K), or PEX5(S)∆C299-PEX5(L)/PEX5R∆N326-EGFP 947 
(SWAP). For clarity reasons, the PEX5(L)-EGFP data are presented in panels (B and C). One 948 
day later, the cells were fixed and processed for immunofluorescence with anti-ABCD3 949 
antibodies. Peroxisome degradation was quantified and plotted as in Figure 2B. The values 950 
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above each bar represent the number of transfected cells analyzed per condition. A 951 
compilation of the results of at least 3 independent experiments (see Fig S23) is shown. The 952 
“>50 peroxisomes” values from the (sub)panels were statistically compared with the value 953 
from the corresponding control (FL) condition (* p<0.05; ** p<0.01). 954 
Figure 5. PEX5-EGFP is monoubiquitinated in a conserved cysteine-dependent manner but 955 
its ATP-dependent export is compromised. (A) Radiolabeled PEX5(L), PEX5(L)-EGFP, 956 
PEX5(L)C11A-EGFP and PEX5(L)C11S-EGFP were added to in vitro import assays in the 957 
presence of Ub aldehyde and either ATP (lanes 2 and 3) or AMP-PNP (lanes 4 and 5). After 958 
incubation at 37°C for 30 min, reactions were treated with NEM and centrifuged to obtain an 959 
organelle pellet (P) and a supernatant (S) fraction. One sixth of both fractions from each 960 
reaction (equivalent to 100 µg of PNS protein) was subjected to SDS-PAGE under 961 
nonreducing conditions and analyzed by autoradiography (an SDS-PAGE analysis of the 962 
same samples but under reducing conditions is shown in Fig. S12). a indicates modified (i.e., 963 
monoubiquitinated; see below) PEX5(L) or PEX5(L)-EGFP species. Lane I, 5% of the 964 
radiolabeled protein used in the assays. (B) Radiolabeled PEX5(L) and PEX5(L)-EGFP were 965 
incubated for 20 min at 37ºC with a postnuclear supernatant in import buffer supplemented 966 
with AMP-PNP. Import reactions were then centrifuged to separate the supernatant (Si) 967 
fraction from organelles (Pi). Isolated organelles were subsequently resuspended in an ATP-968 
containing buffer, incubated for 5 min at 37ºC, and again centrifuged to separate the 969 
suspension into an organelle pellet (Pe) and supernatant (Se) fraction. Samples were separated 970 
under nonreducing conditions by SDS-PAGE and blotted onto a nitrocellulose membrane. 971 
The membrane was exposed to an x-ray film and afterwards probed with an antibody against 972 
ABCD3, a peroxisomal membrane protein. a indicates modified (i.e., monoubiquitinated; see 973 
below) PEX5(L) or PEX5(L)-EGFP species, respectively. Si, equivalent to 50 μg of PNS 974 
protein; Pi, Pe, and Se, equivalent to 250 μg of PNS protein. Lanes I1 and I2, 10% of the 975 
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radiolabeled proteins used in the assay. (C) Import assays made in the presence of GST-Ub 976 
show that the modified PEX5(L) species correspond to monoubiquitinated forms. PEX5(L) 977 
and PEX5(L)-EGFP were subjected to in vitro import reactions containing 3 mM AMP-PNP 978 
in the presence of either Ub or GST-Ub. After incubation, NEM was added and the organelles 979 
were isolated by centrifugation and analyzed by SDS-PAGE/autoradiography under reducing 980 
(+ DTT) or nonreducing (- DTT) conditions. a and b represent PEX5(L)/PEX5(L)-EGFP 981 
species containing one Ub and one GST-Ub, respectively. Lanes I1 and I2, 5% of the 982 
radiolabeled protein used in the assay. Numbers to the left indicate molecular masses of 983 
protein standards (in kDa). 984 
Figure 6. Monoubiquitinated PEX5-EGFP trapped at the DTM in the presence of ATP is only 985 
partially protease protected. Radiolabeled PEX5(L), PEX5(L)-EGFP and PEX5(L)C11A-EGFP 986 
were subjected to in vitro import assays in the presence of Ub aldehyde and either ATP or 987 
AMP-PNP, as indicated. After incubation at 37ºC, organelle suspensions were treated with 988 
proteinase K. NEM-treated organelles were then isolated, and subjected to SDS-PAGE under 989 
reducing (+ DTT) and non-reducing (- DTT) conditions. The autoradiographs (upper panels) 990 
and a section of the corresponding Ponceau S-stained membranes (lower panels) are shown. a 991 
and b represent DTM-inserted PEX5(L) exposing 2 kDa of its N terminus to the cytosol and 992 
DTM-embedded monoubiquitinated PEX5(L), respectively.21 The asterisks mark a set of 993 
PEX5(L)-EGFP-derived fragments that are protease resistant. Lanes I1, I2, I3, 5% of the 994 
radiolabeled protein used in the assays. 995 
Figure 7. Downregulation of PEX1, SQSTM1, or NBR1 does not influence PEX5-EGFP-996 
induced peroxisome removal. SV40T-MEFs were sequentially transfected with scrambled 997 
(NC1), PEX1-, SQSTM-, or NBR1-specific duplex siRNAs (DS) in combination or not with 998 
plasmids encoding mitochondria-targeted EGFP (marker for transfected cells) and (A, C) 999 
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HsPEX5-EGFP or (B) HsPEX5 (for details, see Materials and Methods). One day later, the 1000 
cells were fixed and processed for immunofluorescence microscopy with anti-PEX14 1001 
antibodies. Peroxisome degradation was quantified and plotted as in Fig. 2B. The values 1002 
above each bar represent the number of transfected cells analyzed per condition. A 1003 
compilation of the results of at least 2 independent experiments (see Fig. S24) is shown. The 1004 
“>50 peroxisomes” values from the (sub)panels were statistically compared with the value 1005 
from the corresponding control (NC1) condition and found not to be statistically different. 1006 
Supplementary Figure legends  1007 
Figure S1. PEX5-EGFP-induced peroxisome removal is not affected by expression of 1008 
mitochondria-targeted EGFP. SV40T-MEFs were transfected with plasmids encoding 1009 
HsPEX5(S)-EGFP (5S-EGFP) or HsPEX5(L)-EGFP (5L-EGFP) in combination (+) or not (-) 1010 
with a plasmid encoding mitochondria-targeted EGFP (mt-EGFP). One day later, the cells 1011 
were fixed and processed for immunofluorescence microscopy. The number of peroxisomes 1012 
per transfected cell was quantified in each condition and plotted as in Figure 2B. The values 1013 
above each bar represent the number of transfected cells analyzed per condition. The results 1014 
are a compilation of at least 3 independent experiments. The “>50 peroxisomes” values from 1015 
the “+” and “-” conditions were statistically compared and found not to be statistically 1016 
significant. 1017 
Figure S2. Expression of PEX5-EGFP triggers the degradation of both peroxisomal 1018 
membrane and matrix proteins. SV40T-MEFs were transfected with a plasmid encoding 1019 
PEX5(L)-EGFP. One day later, the cells were fixed, counterstained with DAPI, and processed 1020 
for immunofluorescence microscopy with antibodies raised against PEX14, ABCD3, 1021 
CAT/catalase, or a mixture of peroxisomal matrix proteins (ab-MF16). Representative images 1022 
are shown. Scale bar: 10 µm. 1023 
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Figure S3. PEX5-EGFP-induced peroxisome removal depends on the amount of input DNA. 1024 
SV40T-MEFs were transiently transfected with a plasmid (1 µg/electroporation) encoding 1025 
mitochondria-targeted EGFP (marker for transfected cells) in combination or not with 1026 
increasing concentrations of a plasmid encoding PEX5(L)-EGFP. One day later, the cells 1027 
were fixed and processed for immunofluorescence microscopy with anti-ABCD3 antibodies. 1028 
In each condition, the number of peroxisomes was quantified in 100 randomly selected 1029 
transfected cells and plotted as in Figure 2B. The values are derived from a single experiment. 1030 
Figure S4. Kinetics of the PEX5-EGFP-induced decrease in peroxisome number. SV40T-1031 
MEFs were cotransfected with plasmids encoding PEX5(S)-EGFP and mitochondria-targeted 1032 
EGFP (marker for transfected cells). The cells were fixed at the indicated time-points post-1033 
transfection and processed for immunofluorescence microscopy with anti-ABCD3 antibodies. 1034 
Peroxisome degradation was quantified as in Figure 2B, and the resulting values were plotted 1035 
as (A) percentages of transfected cells, or (B) percentages of transfected cells without 1036 
peroxisomes (PO). The values in (A) are derived from one representative experiment. (B) N, 1037 
number of independent experiments. 1038 
Figure S5. Large monomeric tags fused to the C terminus of PEX5 trigger the removal of 1039 
peroxisomes in MEFs. SV40T-MEFs were transfected with a plasmid encoding PEX5(L)-1040 
HaloTag (PEX5(L)-HT) or PEX5(L)-mCherry. One day later, the cells were fixed, 1041 
counterstained with DAPI, and processed for immunofluorescence microscopy with 1042 
antibodies raised against HaloTag or PEX14. Representative images are shown. Scale bar: 10 1043 
µm. 1044 
Figure S6. The basal turnover rates of peroxisomes in MEFs are not high enough to consider 1045 
a reduction in peroxisome formation as the causal factor for the PEX5-EGFP-induced 1046 
phenotype. SV40T-MEFs, transiently transfected with a plasmid encoding HaloTag-HsHAO2 1047 
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(H-PTS1), were sequentially incubated with the red-fluorescent HaloTag TMR (TMR) ligand 1048 
(4-22 h post-transfection) and the green fluorescent HaloTag R110Direct (R110) ligand (31-1049 
48 h post-transfection; this condition was included to visualize transfected cells in case the 1050 
basal turnover rates of peroxisomes would be very high). The cells were subjected to live-cell 1051 
imaging at 24 and 48 h post-transfection. (A) Schematic overview of the procedure. (B) 1052 
Representative staining patterns of cells expressing H-PTS1. Scale bar: 10 µm. (C) The 1053 
number of TMR-positive peroxisomes in each transfected cell was counted and catalogued as 1054 
more than 50 (>50), between 1 and 50 (1-50), or none (0). 1055 
Figure S7. Number of peroxisomes in SV40T-MEFs. (A) Control (CT) and (B) Atg5+/+ or 1056 
atg5-/- SV40T-MEFs were transiently transfected with a plasmid encoding mitochondria-1057 
targeted EGFP (marker for transfected cells) in combination or not (-) with a plasmid 1058 
encoding PEX5(L)-EGFP (5-EGFP). One day later, the cells were fixed and processed for 1059 
immunofluorescence microscopy with anti-ABCD3 antibodies. In each condition, the number 1060 
of peroxisomes was counted in randomly selected transfected cells. The results are presented 1061 
as box-plot diagrams. The bottom and top of each box represent the 25th and 75th percentile 1062 
values, respectively; the horizontal line inside each box depicts the median; and the horizontal 1063 
lines below and above each box denote the mean minus and plus the standard deviation, 1064 
respectively. The number of cells analyzed per condition is indicated above each 1065 
measurement. The data were statistically compared: statistically significant differences 1066 
(p<0.01) between cells from the same cell line expressing or not PEX5(L)-EGFP are indicated 1067 
with an asterisk (*); significant differences (p<0.01) between identical conditions in different 1068 
cell lines are marked with an alpha symbol (α). The results from a single experiment are 1069 
shown. 1070 
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Figure S8. Expression of PEX5-EGFP does not increase the levels of LC3-II in the absence 1071 
or presence of bafilomycin A1. SV40T-MEFs were either not transfected (-) or co-transfected 1072 
with a plasmid encoding EGFP-MAP1LC3 (GFP-LC3) and PEX5(L)C11A-EGFP or PEX5(L)-1073 
EGFP. Eight h later, the cells were incubated (+) or not (-) with 100 nM of bafilomycin A1. 1074 
Two h later, whole cell lysates were processed for SDS-PAGE, Ponceau S staining (to 1075 
visualize total protein), and immunoblotting with antibodies against MAP1LC3B (LC3). The 1076 
migration points of relevant molecular mass markers (expressed in kDa) are shown on the 1077 
left. The arrowheads mark nonspecific protein bands. The numbers between brackets indicate 1078 
the transfection efficiencies. 1079 
Figure S9. PEX5-EGFP expression does not affect the normal distribution and morphology 1080 
of mitochondria and the ER. SV40T-MEFs were transfected with a plasmid encoding 1081 
PEX5(S)-EGFP. One day later the cells were treated with either (upper panels) MitoTracker® 1082 
Red CM-H2Xros (MitoTracker) or (lower panels) ER-Tracker
TM Blue-White DPX (ER-1083 
Tracker; recolored in red) to visualize the mitochondria and the ER, respectively. 1084 
Representative images are shown. Scale bar: 10 µm. 1085 
Figure S10. EGFP-tagged PEX5 proteins partially localize to peroxisomes. SV40T-MEFs 1086 
were transfected with plasmids encoding either PEX5(S)-EGFP (upper panels), PEX5(L)C11S-1087 
EGFP (middle panels), or PEX5(L)C11A-EGFP (lower panels). One day later, the cells were 1088 
fixed, counterstained with DAPI, and processed for immunofluorescence microscopy with 1089 
anti-ABCD3 antibodies followed by TxRed-conjugated secondary antibodies. Scale bar: 10 1090 
µm. 1091 
Figure S11. PEX5-EGFP, PEX5C11A-EGFP, and PEX5C11S-EGFP are expressed at similar 1092 
levels. SV40T-MEFs were transfected with a plasmid encoding mitochondria-targeted EGFP 1093 
(marker for transfected cells) in combination or not (-) with PEX5(L)-EGFP (WT), 1094 
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PEX5(L)C11A-EGFP (C11A), or PEX5(L)C11S-EGFP (C11S). One day later, whole cell lysates 1095 
were subjected to SDS-PAGE and processed for immunoblotting. (A) Anti-EGFP (upper part) 1096 
and anti-ACTB/β-actin (lower part) staining patterns. The migration points of relevant 1097 
molecular mass markers (expressed in kDa) are shown on the right. (B) The anti-EGFP 1098 
signals were quantified and normalized to ACTB. Note that (i) the transfection efficiencies 1099 
were similar (30-37%) for all conditions, and (ii) the level of pexophagy induction by each 1100 
PEX5-EGFP variant was comparable to that shown in Fig. 4B (data not shown). The results 1101 
from a single experiment are shown. 1102 
Figure S12. Reducing SDS-PAGE analysis of the in vitro import reactions performed with 1103 
radiolabeled PEX5(L), PEX5(L)-EGFP, PEX5(L)C11A-EGFP and PEX5(L)C11S-EGFP. 1104 
Fractions from the in vitro assays shown in Fig. 5A (one sixth of each fraction) were 1105 
subjected to SDS-PAGE under reducing conditions. An autoradiograph is shown. Numbers to 1106 
the left indicate molecular masses of protein standards (in kDa). 1107 
Figure S13. The organelle-associated protease-resistant domains of Ub-PEX5(L)-EGFP 1108 
represent C-terminal fragments of PEX5(L) including EGFP. Radiolabeled PEX5(L)-EGFP 1109 
was subjected to an in vitro import reaction in the presence of ATP. After protease treatment, 1110 
the organelles were isolated and solubilized with immunoprecipitation buffer. The clarified 1111 
supernatant (Total), the immunoprecipitates (IP) obtained using either an anti-EGFP (GFP) or 1112 
control serum (Ctrl), and the corresponding immunodepleted supernatant fractions (ID) were 1113 
analyzed by SDS-PAGE/autoradiography. Numbers to the left indicate the molecular masses 1114 
of protein standards (in kDa). F, front. 1115 
Figure S14. PEX5-EGFP is posttranslationally modified in a conserved cysteine-dependent 1116 
manner upon expression in MEFs. SV40T-MEFs were either not transfected (-) or transfected 1117 
with a plasmid encoding PEX5C11A-EGFP (C11A) or PEX5-EGFP (WT). One day later, 1118 
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whole cell lysates were subjected to SDS-PAGE under nonreducing (- DTT) or reducing (+ 1119 
DTT) conditions and processed for immunoblotting with antibodies against PEX5. Arrows 1120 
and arrowheads mark PEX5-specific and -nonspecific bands, respectively. The migration 1121 
points of relevant molecular mass markers (expressed in kDa) are shown on the left. 1122 
Figure S15. SV40 large T antigen does not affect the expression levels of pEGFP-N1-1123 
encoded proteins in MEFs. Spontaneously- (S) or SV40 large T antigen (SVT)-transformed 1124 
MEFs were either not transfected (-) or transfected with a plasmid encoding PEX5(L)-EGFP 1125 
(5-EGFP) or mitochondria-targeted EGFP (mt-EGFP). One day later, whole cell lysates were 1126 
subjected to SDS-PAGE and processed for immunoblotting with antibodies against EGFP. 1127 
The migration points of relevant molecular mass markers (expressed in kDa) are shown on the 1128 
left. Note that mt-EGFP contains 2 mitochondrial targeting signals arranged in tandem and 1129 
that the arrows in the lower panel mark the differentially cleaved isoforms of this protein. The 1130 
numbers between brackets indicate the transfection efficiencies. 1131 
Figure S16. Ability of different PEX5 proteins to complement or inhibit peroxisomal matrix 1132 
protein import. SV40T-PEX5-/- human fibroblasts (PEX5-/- SV40T-HuFs) or spontaneously 1133 
transformed Sqstm1+/+ mouse embryonic fibroblasts (MEFs) were transfected with a plasmid 1134 
encoding peroxisomal mCherry (mCherry-PTS1) together or not (-) with a plasmid encoding 1135 
either wild-type HsPEX5(L) (WT), HsPEX5(L)C11K (C11K), HsPEX5(L)C11S (C11S), 1136 
HsPEX5(L)C11A (C11A), or HsPEX5(L)-EGFP (GFP). The subcellular distribution pattern of 1137 
mCherry-PTS1 was analyzed at the indicated days post-transfection (dpt): PO, peroxisomal; 1138 
PO/C, mixed peroxisomal-cytosolic; and C, cytosolic. Representative images of the observed 1139 
patterns are shown for each cell type (scale bar: 10 µm). (A) Complementation activity of 1140 
PEX5 variants in PEX5-/- SV40T-HuFs. The results are plotted as percentage-based stacked 1141 
bar charts (n = 100). (B) Inhibitory activity of PEX5 variants on peroxisomal matrix protein 1142 
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import in Sqstm1+/+ MEFs. The results are plotted as percentage-based stacked bar charts (n = 1143 
150). 1144 
Figure S17. Efficiency of DsiRNA delivery. SV40T-MEFs were sequentially transfected with 1145 
a non-fluorescently- (DS NC1) or fluorescently-labeled (DS TYE 563) scrambled control 1146 
RNA duplex (for details, see Materials and Methods). Six h after the second transfection, the 1147 
nuclei were stained with Hoechst 33258 and the cells were processed for live-cell imaging. 1148 
Representative images are shown. Scale bar: 50 µm. 1149 
Figure S18. Effect of downregulation of PEX1 on PTS1 protein import. SV40T-MEFs were 1150 
sequentially transfected with scrambled (DS NC1) or PEX1-specific duplex siRNAs (DS 1151 
PEX1) in combination or not with a plasmid encoding peroxisome-targeted EGFP (EGFP-1152 
PTS1) (for details, see Materials and Methods). One day later, the cells were (A) fixed and 1153 
processed for immunofluorescence microscopy with antibodies against PEX1 or PEX14 1154 
(scale bar: 10 µm), (B) processed for immunoblotting with antibodies against PEX1 (the 1155 
migration point of a relevant molecular mass marker (expressed in kDa) is shown on the right; 1156 
the asterisk indicates a nonspecific protein band recognized by the anti-PEX1 antibody), or 1157 
(C) analyzed by live-cell imaging to determine the subcellular distribution pattern of EGFP-1158 
PTS1 (PO, peroxisomal; PO/C, mixed peroxisomal-cytosolic; and C, cytosolic; the results are 1159 
plotted as percentage-based stacked bar charts; n > 450). 1160 
Figure S19. Downregulation of SQSTM1 and NBR1 in SV40T-MEFs. SV40T-MEFs were 1161 
sequentially transfected with scrambled (NC1) or SQSTM1- or NBR1-specific duplex 1162 
siRNAs (DS) in combination or not with a plasmid encoding PEX5-EGFP (for details, see 1163 
Materials and Methods). One day later, the cells were (A, B) fixed and processed for 1164 
immunofluorescence microscopy with antibodies against SQSTM1, NBR1 or PEX14 (scale 1165 
bar: 10 µm), or (C, D) first incubated (+) or not (-) with 100 nM bafilomycin A1 (baf A1) for 3 1166 
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h and subsequently processed for immunoblotting with antibodies against SQSTM1 or NBR1. 1167 
The migration points of relevant molecular mass markers (expressed in kDa) are shown on the 1168 
left. The asterisk marks a degradation product of SQSTM1, and the arrowheads mark 1169 
nonspecific protein bands. 1170 
Figure S20. Peroxisomes do not cluster or colocalize with EGFP-MAP1LC3B during PEX5-1171 
mediated pexophagy. SV40T-MEFs were cotransfected with plasmids encoding EGFP-1172 
MAP1LC3B and either FLAG-SLC25A17-Ub (upper panels) or PEX5(L)-KR (lower panels) 1173 
in the presence (lower panels) or not (upper panels) of 100 nM bafilomycin A1. 12 h later, the 1174 
cells were fixed and processed for immunofluorescence microscopy with anti-FLAG and/or 1175 
anti-ABCD3 antibodies followed by TxRed- and/or Alexa Fluor 350-conjugated secondary 1176 
antibodies. Representative images are shown. Scale bar: 10 µm. 1177 
Figure S21. Expression of PEX5 proteins fused to a bulky C-terminal tag promotes a 1178 
decrease in peroxisome number. SV40T-MEFs were cotransfected with plasmids encoding 1179 
mitochondria-targeted EGFP (marker for transfected cells) and either (A) HsPEX5(S), (B) 1180 
HsPEX5(S)-FLAG, (C) EGFP-HsPEX5(S), (D) HsPEX5(S)-EGFP, (E) HsPEX5(L), (F) 1181 
HsPEX5(L)-EGFP, (G) HsPEX5(L)-KR, or (H) MmPEX5(L)-EGFP. One day later, the cells 1182 
were fixed, counterstained with DAPI, and processed for immunofluorescence microscopy 1183 
with anti-ABCD3 antibodies followed by TxRed- or Alexa Fluor 488-conjugated secondary 1184 
antibodies. The number of peroxisomes in each transfected cell was counted and catalogued 1185 
as more than 50 (>50), between 1 and 50 (1-50), or none (0). The average percentage of 1186 
transfected cells displaying each phenotype is plotted. The error bars represent the standard 1187 
deviations. N, number of independent experiments. 1188 
Figure S22. PEX5-EGFP-induced peroxisome removal is dependent on autophagy. (A) 1189 
Atg5+/+, (B) atg5-/- or (C-E) control (CT) SV40T-MEFs were cotransfected with plasmids 1190 
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encoding mitochondria-targeted EGFP (marker for transfected cells) and a plasmid encoding 1191 
PEX5-EGFP in the absence (A-C) or presence (D) of 10 mM 3-methyladenine (3-MA) or (E) 1192 
10 µM LY294002 (LY). One day later, the cells were fixed and processed for 1193 
immunofluorescence microscopy with either anti-ABCD3 or anti-PEX14 antibodies. The 1194 
number of peroxisomes in each transfected cell was quantified and plotted as in Figure S21. 1195 
The error bars represent the standard deviations. N, number of independent experiments.  1196 
Figure S23. The N-terminal cysteine residue that marks PEX5 for recycling is crucial for 1197 
PEX5-EGFP-induced pexophagy. SV40T-MEFs were cotransfected with plasmids encoding 1198 
mitochondria-targeted EGFP (marker for transfected cells) and either (A) HsPEX5(S)-EGFP, 1199 
(B) HsPEX5(S)∆N16-EGFP, (C) HsPEX5(S)∆N110-EGFP, (D) HsPEX5(L), (E) HsPEX5(L)C11S, 1200 
(F) HsPEX5(L)C11A, (G) HsPEX5(L)-EGFP, (H) HsPEX5(L)C11S-EGFP, (I) HsPEX5(L)C11A-1201 
EGFP, (J) HsPEX5(L)C11K-EGFP, (K) PEX5(L)K527R-EGFP, (L) PEX5(L)N526K-EGFP, or (M) 1202 
PEX5(S)∆C299-PEX5L/PEX5R∆N326-EGFP (HsPEX5(S)SWAP-EGFP). One day later, the cells 1203 
were fixed and processed for immunofluorescence microscopy with anti-ABCD3 antibodies 1204 
followed by TxRed-conjugated secondary antibodies. The number of peroxisomes in each 1205 
transfected cell was quantified and plotted as in Figure S21. The error bars represent the 1206 
standard deviations. N, number of independent experiments. 1207 
Figure S24. Downregulation of SQSTM1, NBR1, or PEX1 does not influence PEX5-EGFP-1208 
induced peroxisome removal. SV40T-MEFs were sequentially transfected with scrambled 1209 
(NC1), SQSTM-, NBR1-, or PEX1-specific duplex siRNAs (DS) in combination or not with 1210 
plasmids encoding mitochondria-targeted EGFP (marker for transfected cells) and HsPEX5-1211 
EGFP (for details, see Materials and Methods). One day later, the cells were fixed and 1212 
processed for immunofluorescence microscopy with anti-PEX14 antibodies followed by 1213 
TxRed-conjugated secondary antibodies. The number of peroxisomes in each transfected cell 1214 
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was quantified and plotted as in Figure S21. The error bars represent the standard deviations. 1215 
N, number of independent experiments. 1216 
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Materials S1 1 
Description of the non-commercial plasmids used in this study 2 
Unless indicated otherwise, all PEX5 constructs described below encode the human 3 
ortholog of this peroxin. The vectors encoding (cytosolic) KR (pMF1755), PEX5(L) 4 
(pMF961), PEX5(L)C11K (pMF1579), PEX5(L)N526K (pMF1698), PEX5(S) (pMF106), 5 
HsPMP34 (pBS-HsPMP34), or PEX5(S)∆C299-PEX5L/PEX5R∆N326-EGFP (pLA142) have 6 
been described elsewhere.1-8 The plasmids encoding myc-tagged MmPEX5(L) (pLA141), 7 
GFP-LC3, LAMP1-EGFP, or LAMP2A-EGFP were acquired from Dr. M. Baes (KU Leuven, 8 
Belgium), Dr T. Yoshimori (National Institute of Genetics, Japan), Dr. T. Voets (KU Leuven, 9 
Belgium), and Dr. S. M. Di Pietro (Colorado State University, CO, USA), respectively. The 10 
plasmid encoding FLAG-PMP34-Ub (pMN19) was generated in 2 steps: first, EcoRI/SalI-11 
flanked Ub-encoding cDNA was isolated from human liver cDNA (TaKaRa, 637205) by PCR 12 
(primers: UbfwEcoRI and UbrvSalI) and cloned into an EcoRI/SalI-restricted pCMV-Tag 2B 13 
vector to yield a plasmid encoding FLAG-Ub (pEA7); second, pMN19 was constructed by 14 
amplification of the PMP34 cDNA by PCR (template: pBS-HsPMP34; primers: 15 
PMP34fwBamHI and PMP34rvEcoRI) and cloning the BamHI/EcoRI-digested PCR product 16 
into the BamHI/EcoRI-cut pEA7. The construct encoding human PEX5(L)-KR (pMF1758) 17 
was generated by cloning the SalI/BglII-restricted PEX5(L)-coding PCR product (template 18 
pMF961; primers: PEX5fwSalI and PEX5rvBglII), and KR from the BamHI/NotI-digested 19 
pKillerRed-dMito vector, into SalI/NotI-restricted pEGFP-N1 via a 3-point ligation 20 
procedure. Also the plasmids encoding PEX5(L)-HaloTag (pMF1677) and HsHAO2 21 
(hydroxyacid oxidase 2)-HaloTag (pMF1633; HaloTag-PTS1) were generated via a 3-point 22 
ligation procedure: pMF1677 was generated by cloning a SalI/BglII-restricted PEX5-23 
encoding PCR fragment (template: pMF961; primers: PEX5fwSalI and PEX5BglIIrv) and a 24 
BamHI/NotI-restricted HaloTag-encoding PCR fragment (template: pHT2; primers: pHT2fw 25 
 2 
and pHT2rvNot) into SalI/NotI-restricted pEGFP-N1; and pMF1633 was generated by 26 
cloning a HindIII/BamHI-restricted HaloTag-encoding PCR fragment (template: pHT2; 27 
primers: pHT2fwHindIII and pHT2rvBamHI) and a BamHI/NotI-restricted HAO2-encoding 28 
PCR fragment (template: human liver cDNA; primers: HAO2fwBamHI and HAO2rvNotI) 29 
into HindIII/NotI-restricted pEGFP-N1. The bicistronic construct encoding peroxisomal 30 
roGFP2 and human PEX5(L)C11S (pDC3) was constructed by amplifying the corresponding 31 
PEX5(L)C11S cDNA fragment by PCR (template pMF1679
7; primers: PEX5fwBglII3 and 32 
PEX5rvSalI2) and cloning the BglII/SalI-digested PCR product into the BglII/SalI-restricted 33 
pIRES2-roGFP2-PTS1 vector.9 The plasmids coding for nontagged PEX5(S) (pMN56), 34 
PEX5(L) (pMN57), PEX5(L)C11S (pMN53), and PEX5(L)C11A (pMN64) were generated via 35 
amplification of the corresponding cDNAs via PCR (templates: pMF106 (pMN56), pMF961 36 
(pMN57), pDC3 (pMN53), and pMN57 (pMN64); primers: PEX5fwBglII1 and PEX5rvNotI 37 
(pMN56, pMN57, pMN53), and PEX5C11AfwBglII and PEX5rvNotI (pMN64)) and cloning 38 
the BglII/NotI-restricted PCR products into BglII/NotI-digested pEGFP-N1. The plasmids 39 
encoding EGFP fused to the C terminus of either PEX5(S) (pLA138), PEX5(L) (pMN65), 40 
PEX5(L)C11S (pMN54), PEX5(L)C11A (pMN63), PEX5(L)C11K (pMN75), PEX5(S)N10 41 
(pMF908), PEX5(S)N110 (pMF916), and PEX5(L)N526K (pMN77) were constructed by 42 
amplifying the corresponding PEX5 cDNAs via PCR (templates: pMN57 (pMN65), 43 
pMF1579 (pMN75), pDC3 (pMN54), pMN53 (pMN63), pMF106 (pLA138, pMF908, 44 
pMF916) and pMF1698 (pMN77); primers: PEX5fwBglII2 and PEX5rvSalI1 (pLA138), 45 
PEX5fwBglII1 and PEX5rvSalI3 (pMN65, pMN54, pMN75, pMN77) PEX5C11AfwBglII and 46 
PEX5rvSalI3 (pMN63), PEX5N10fwBglII and PEX5rvSalI3 (pMF908), PEX5N110fwBglII 47 
and PEX5rvSalI3 (pMF916)) and cloning the BglII/SalI-digested PCR products into the 48 
BglII/SalI-restricted pEGFP-N1 vector. The plasmid encoding PEX5(L)-mCherry (pMN78) 49 
was generated by replacing the SalI/NotI-restricted EGFP cassette by a SalI/NotI-restricted 50 
 3 
mCherry cassette (this cassette was amplified by PCR (template: pJ1:PG27188 (DNA2.0); 51 
primers: mCherrySalIfw and mCherryNotIrv)). The plasmid encoding PEX5(S)N489K-EGFP 52 
(pMN80) was generated by cloning the HindIII/NotI-restricted insert of pMN77 into the 53 
HindIII/NotI-restricted backbone of pMN56. To generate the plasmid coding for the fusion 54 
protein PEX5(S)∆C299-PEX5L/PEX5RN326-EGFP (pMN70), the BglII/SalI-restricted PCR 55 
product (template: pLA142; primers: PEX5fwBglII1 and PEX5RrvSalI) was cloned into the 56 
BglII/SalI-digested pEGFP-N1 vector. The plasmid encoding human PEX5(L)K527R-EGFP 57 
(pMN71) was generated by amplifying the cDNA encoding PEX5(L)K527R via fusion PCR and 58 
cloning the corresponding BglII/SalI-digested PCR product into the backbone fragment of 59 
BglII/SalI-restricted pEGFP-N1. The fusion PCR product was generated as follows: in a first 60 
PCR reaction, 2 PCR fragments (template: pMN57; primers PEX5fwBglII1 and PEX5K527Rrv 61 
(fragment 1), PEX5K527Rfw and PEX5rvSalI3 (fragment 2)) were generated; these fragments 62 
were fused and used as template in a second PCR reaction generating the final cDNA 63 
(primers: PEX5fwBglII1 and PEX5rvSalI3). The plasmid encoding MmPEX5(L)-EGFP 64 
(pMN62) was generated by cloning the NheI/SalI digested MmPEX5(L) PCR product 65 
(template: pLA141; primers: PEX5fwNheI and PEX5rvSalI4) into the NheI/SalI-restricted 66 
backbone fragment of pEGFP-N1. The pGEM-based vectors encoding EGFP-tagged 67 
PEX5(L) (pMN66), PEX5(L)C11K (pMN76), PEX5(L)C11S (pMN67) and PEX5(L)C11A 68 
(pMN68) were generated by amplifying the corresponding cDNAs via fusion PCR and 69 
cloning the SalI/BglII-restricted PCR products into the backbone fragment of a SalI/BamHI-70 
digested pGEM-4 vector. The fusion PCR products were generated as follows: in a first PCR 71 
reaction, 2 PCR fragments (template: pMN65 (pMN66), pMN54 (pMN67), pMN63 72 
(pMN68), pMF1579, and pMN65 (pMN76); primers: PEX5fwSalI and PEX5fusionrv 73 
(fragment 1), PEX5fusionfw and EGFPrvBglII (fragment 2)) were generated; these fragments 74 
 4 
were fused and used as template in a second PCR reaction generating the final cDNAs 75 
(primers: PEX5fwSalI and EGFPrvBglII). 76 
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Table S1. List of oligonucleotides used in this study. 1 
Name Nucleotide sequence 
EGFPrvBglII  
HAO2fwBamHI 
HAO2rvNotI 
mCherryNotIrv 
mCherrySalIfw 
PEX5BglIIrv 
PEX5C11AfwBglII 
PEX5fusionfw 
PEX5fusionrv 
PEX5fwBglII1 
PEX5fwBglII2 
PEX5fwBglII3 
PEX5fwNheI 
PEX5fwSalI 
PEX5N10fwBglII 
PEX5N110fwBglII 
PEX5K527Rfw 
PEX5K527Rrv 
PEX5rvBglII 
PEX5rvNotI 
PEX5rvSalI1 
PEX5rvSalI2 
PEX5rvSalI3 
PEX5rvSalI4 
5’-gagaagatctttacttgtacagctcgtcc-3’ 
5’-gggggatccatgtccttggtgtgtctg-3’ 
5’-ggggcggccgcttacagcctggaaaactggac-3’ 
5’-ggcggggcggccgcttacttgtacagctcgtcc-3’ 
5’-gccggtcgacaccggtcgccaccatggtgagcaagggcgag-3’ 
5’-gggagatctccctggggcaggccaaacatag-3’ 
5’-ggggagatctaccatggcaatgcgggagctggtggaggccgaaGCcgggggtgccaacc-3’ 
5’-ccagctctcgacggtaccgcggg-3’ 
5’-gtaccgtcgagagctggggcaggccaaac-3’ 
5’-gggagatctaccatggcaatgcgggagctg-3’ 
5’-gggagatctatggcaatgcgggagctggtg-3’ 
5’-cgagatctgtatggcaatgcgggagctgg-3’ 
5’-cggcgggctagcaccatggcaatgcgggagctg-3’ 
5’-ggcgggtcgacgtcaccatggcaatgcgggag-3’ 
5’-gggagatctaccatggcaatgaagctcgccgggcac-3’ 
5’-gggagatctaccatggcagacttggccttgtct-3’ 
5’-gctgtggaataGgctaggcgccaccctg-3’ 
5’-cctagcCtattccacagcaaatagtcattg-3’ 
5’-gggagatctccctggggcaggccaaacatag-3’ 
5’-gggggcggccgctcactggggcaggccaaac-3’ 
5’-ccttcgtcgactggggcaggccaaacatag-3’ 
5’-gcccgtcgacctgtcactggggcaggccaaac-3’ 
5’-gagaggtcgacagctggggcaggccaaacatagt-3’ 
5’-gagaggtcgacagctggggcaggccaaacatag-3’ 
 2 
PEX5RrvSalI 
pHT2fw 
pHT2fwHindIII 
pHT2rvBamHI 
pHT2rvNotI 
PMP34fwBamHI 
PMP34rvEcoRI  
UbfwEcoRI 
UbrvSalI 
5’-gggggtcgactgaggatccaagttgaaagctc-3’ 
5’-gggggtaccggatccgatggggtccgaaatcggtacaggc-3 
5’-gggaagcttaccatggggtccgaaatcggtac-3’ 
5’-gggggatccgccgccggccagcccggggag-3’ 
5’-agggaagcggccgcctactt-3’ 
5’-gagcggatccatggcttccgtgctgtcc-3’ 
5’-gcggaattcgcctccgtgttggtgtgcacgctt-3’ 
5’-ggcgcgaattcatgcagatcttcgtgaagactc-3’ 
5’-gttttgtcgacctacccacctctgagacggagcac-3’ 
Restriction sites are underlined. Nucleotides in bold capital letters represent the C11A and K527R mutations. 2 
